Bikaner | A Continuing Medical Education (CME) programme focusing on advanced management of hemophilia inhibitors was successfully organized in Bikaner, bringing together pediatric specialists and medical professionals to discuss emerging treatment strategies and clinical challenges.
Organized under the aegis of the Bikaner Pediatric Society, the event on May 2 at Rani Bazar saw participation from over 50 pediatricians, faculty members, and resident doctors.
Addressing a Critical Challenge in Hemophilia
The session was inaugurated by Prof. (Dr.) G.S. Tanwar, Head of Department at PBM Hospital’s pediatric unit, who described inhibitors in Hemophilia as one of the most significant clinical challenges. He emphasized that prolonged joint bleeding or unusually high requirement of clotting factors should alert clinicians to the possibility of inhibitor development.
Highlighting the importance of timely screening and early diagnosis, he stressed that appropriate treatment strategies can significantly improve patient outcomes.
New-Age Therapies Offer Hope
Experts discussed treatment approaches based on low-titer and high-titer inhibitors, with particular focus on bypassing agents such as FEIBA and Recombinant Factor VIIa.
A major highlight of the discussion was Emicizumab, which was described as a “game changer” in hemophilia care due to its ability to reduce bleeding episodes and improve quality of life. Experts also touched upon the future potential of gene therapy in offering long-term solutions for affected children.
Scientific Sessions and Practical Insights
During the scientific sessions, Dr. Gaurav Gomber and Dr. Shyam Agarwal presented detailed insights into the evolution of inhibitor management—from historical approaches to modern therapeutic advancements.
The interactive Q&A session saw resident doctors raising practical concerns regarding inhibitor testing, use of bypassing agents, emicizumab, and immune tolerance therapy. Experts responded with clinically relevant and easy-to-apply guidance.
Vision for a Centre of Excellence
Concluding the programme, Prof. Tanwar underscored the principle of “Suspect, Test, and Treat” as the cornerstone of effective hemophilia management. He also expressed optimism about developing Bikaner into a Centre of Excellence for hemophilia care in the future.
The event concluded with a commitment to continue organizing such academic initiatives regularly, ensuring that healthcare professionals remain updated with the latest advancements in medical science and patient care.
